Boceprevir in genotype 1 chronic hepatitis C: First experiences in Serbia
نویسندگان
چکیده
منابع مشابه
Adverse Skin Reactions during Triple Therapy with Boceprevir in Chronic Hepatitis C Genotype 1
Boceprevir is a first generation serin protease NS3/4A inhibitor, formally available in Italy from 2013 and often used for the treatment of CHC genotype 1, always in combination with pegylated interferon and ribavirin; known as the triple therapy. The main advantages of using boceprevir are the higher SVR percentage and shorter treatment time; 28 weeks if eRVR-extended rapid virological respons...
متن کاملTreatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virolog...
متن کاملCost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.
BACKGROUND The recent approval of two protease inhibitors, boceprevir and telaprevir, is likely to change the management of chronic hepatitis C virus (HCV) genotype 1 infection. OBJECTIVES We evaluated the long-term clinical outcomes and the cost effectiveness of therapeutic strategies using boceprevir with peginterferon plus ribavirin (PR) in comparison with PR alone for treating HCV genotyp...
متن کاملViral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C.
OBJECTIVE to identify predictive factors of response to pegylated interferon alpha-2b and ribavirin in patients with genotype 1 chronic hepatitis C. Viral kinetics were studied in weeks 2 and 4. METHODS a prospective and consecutive study of patients with genotype 1 chronic hepatitis C referred to our Hepatology Clinic between January 2004 and October 2006 for antiviral treatment. Baseline da...
متن کاملBoceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
BACKGROUND SPRINT-2 demonstrated that boceprevir (BOC), an oral hepatitis C virus (HCV) nonstructural 3 (NS3) protease inhibitor, added to peginterferon alfa-2b (P) and ribavirin (R) significantly increased sustained virologic response rates over PR alone in previously untreated adult patients with chronic HCV genotype 1. We estimated the long-term impact of triple therapy vs. dual therapy on t...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Srpski arhiv za celokupno lekarstvo
سال: 2015
ISSN: 0370-8179,2406-0895
DOI: 10.2298/sarh1502035s